Keywords: Eli Lilly, NICE, Alimta, non-squamous NSCLC, Lung cancer

Eli Lilly’s Alimta gains backing from UK’s NICE as maintenance therapy for advanced, non-squamous NSCLC

Article | 07 April 2010

Print This

In an about turn by the UK’s National Institute for Health and Clinical Excellence (NICE), the agency has given ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in